What causes recurrent SIBO?

The Host Capacity Model identifies colonocyte bioenergetic failure as the upstream driver of recurrent SIBO. When colonocyte mitochondrial respiration fails, oxygen leaks into the lumen and reshapes the ecology toward facultative and sulfidogenic overgrowth—so antimicrobials clear the symptom but not the cause.

How is MCAS different from other mast cell conditions?

BiomeLogic stratifies MCAS into Pattern A/B/C/D activation phenotypes based on upstream drivers (barrier, neuroimmune, infectious, or connective-tissue mediated). Treatment differs by pattern, which is why generic mast-cell stabilizers fail in many patients.

Do you provide medical care or diagnoses?

No. BiomeLogic provides independent systems-biology consultation and mechanistic case analysis. It is not medical care, not a diagnosis, and does not replace your physician.

Post-COVID Mast Cell Activation Syndrome (MCAS)

Post-COVID MCAS is not random. It is the convergence of genetic predisposition (HαT, MTHFR, AOC1, ACE2 variants), direct spike-protein triggering of mast cells via ACE2, NAD⁺-dependent loss of SIRT1 chromatin restraint, and durable epigenetic reprogramming of bone marrow progenitors that produce reactive mast cells for years after the acute infection.

The four genetic layers of vulnerability

Layer 1 — entry genetics (ACE2 rs2285666, TMPRSS2): determines viral penetration depth. Layer 2 — mast cell load (TPSAB1/HαT, KIT): determines basal mast cell reactivity. Layer 3 — clearance genetics (AOC1/DAO, HNMT): determines histamine clearance capacity. Layer 4 — methylation (MTHFR C677T/A1298C, COMT): determines whether HNMT and inflammatory transcription stay calibrated.

Three simultaneous mechanisms during acute COVID

Mechanism 1: Spike protein binds ACE2 on mast cells and triggers degranulation within minutes. Mechanism 2: SARS-CoV-2 upregulates CD38, depleting NAD⁺ and disabling SIRT1 — which removes the chromatin lock on mast cell inflammatory genes. Mechanism 3: epigenetic reprogramming of hematopoietic stem cells (Cell, 2023) produces hyperreactive mast cells for months to a year after recovery.

Why standard antihistamines fail

H1/H2 blockers address downstream mediators but do not restore SIRT1 chromatin restraint, repair the methylation cycle, or reprogram bone marrow progenitors. Durable recovery requires addressing NAD⁺ economy, methylation capacity, mast cell membrane stability, and the gut-mast cell axis simultaneously.

Key terms

MCAS: Mast Cell Activation Syndrome — a condition where mast cells release inflammatory mediators inappropriately, producing multi-system symptoms (flushing, GI dysfunction, brain fog, cardiovascular instability).
HαT: Hereditary Alpha-Tryptasemia — extra copies of TPSAB1 producing elevated baseline tryptase and primed mast cells. Present in ~5% of Western populations.
SIRT1: NAD⁺-dependent deacetylase that maintains H3K9me3 chromatin marks suppressing mast cell inflammatory gene expression.

Why Dysbiosis, SIBO, Hydrogen Sulfide Intolerance, MCAS, and Long COVID May All Be Downstream of a Single Event · June 11, 2026 · 28 min
What Actually Causes Fibromyalgia? The Mitochondrial, Mast Cell, and Small Fiber Neuropathy Mechanisms Standard Treatment Misses · June 1, 2026 · 22 min
What Actually Causes Chronic Migraine? A Mechanistic Reading of Treatment-Resistant Migraine · May 31, 2026 · 22 min
Why Does Endometriosis Come Back After Surgery? The Gut, Estrobolome, and Bioenergetic Mechanism · May 30, 2026 · 21 min
What Actually Causes POTS? A Mechanistic Reading of Postural Orthostatic Tachycardia Syndrome · May 28, 2026 · 19 min
Why Does MCAS Not Respond to Standard Treatment? The Four Mechanistically Distinct Patterns · May 26, 2026 · 18 min
The Mycotoxin-Mitochondria Trap: Why Standard Detox Fails in Chronic Illness, and How to Escape It · May 14, 2026 · 12 min
Why Your Chronic Illness Got Dramatically Worse in Perimenopause: The Hormonal Cascade Driving Gut, Mast Cell, Brain Fog, and Fatigue Symptoms in Your 40s · May 14, 2026 · 32 min
Why Your Brain Fog Won't Lift: The Six Mechanisms of Cognitive Dysfunction in Chronic Illness, and Why Standard Interventions Keep Failing · May 14, 2026 · 30 min
Histamine Intolerance: Why the DAO Enzyme Story Is Incomplete, and the Real Reason Your Low Histamine Diet Stopped Working · May 14, 2026 · 26 min
Why hEDS, POTS, and MCAS Almost Always Come Together: The Mechanistic Triad and the Upstream Lesion Standard Medicine Doesn't Treat · May 14, 2026 · 28 min
Why Long COVID Won't Resolve: A Mechanistic Reading of Viral Persistence, Mitochondrial Dysfunction, and the Gut–Brain Axis the Standard Model Is Missing · May 14, 2026 · 32 min

Frequently asked

Why did I develop MCAS after COVID but my friend didn't?

Genetic background. Variants in TPSAB1 (Hereditary Alpha-Tryptasemia, ~5% of population), MTHFR, AOC1, and ACE2 stack predisposition. COVID converts a latent vulnerability into an active, epigenetically locked syndrome.

Can post-COVID MCAS be reversed?

The bone marrow progenitor reprogramming is durable but not necessarily permanent. Recovery requires addressing NAD⁺ depletion, restoring SIRT1 function, supporting methylation, repairing the gut barrier, and stabilizing mast cell membranes — not just blocking histamine.